General Discussion
Related: Editorials & Other Articles, Issue Forums, Alliance Forums, Region ForumsThis One Drug Will Make Medicare Premiums Skyrocket
Dec 16, 2021
Seniors will pay record-high Medicare premiums in 2022 after the FDA approved an Alzheimers drug that costs $56,000 over the objections of medical advisors. There is zero evidence that the drug cures or reverses Alzheimer's. Three FDA administrators quit in protest.
Biden must act stop this outrageous increase in Medicare premiums.
NewHendoLib
(61,700 posts)ridiculous
so if they reverse it, they'd have to offer refunds to make it fair.
dalton99a
(92,875 posts)Hoyt
(54,770 posts)Im hopeful the drug, and treatments that may come about, will work.
LiberalArkie
(19,495 posts)rockfordfile
(8,742 posts)George II
(67,782 posts)dhol82
(9,639 posts)Sucks big time.
Elwood P Dowd
(11,453 posts)The acting commissioner is Janet Woodcock. Why did she let this happen? Anyone know the details?
dhol82
(9,639 posts)Elwood P Dowd
(11,453 posts)Donkees
(33,525 posts)Nov 12, 2021
President Joe Biden has officially nominated former Obama administration pick Robert Califf, M.D., as his new FDA commissioner.
This comes right before Nov. 15, the final day Janet Woodcock, M.D., the acting commissioner, can stay in the interim role, and 10 months after Bidens inauguration.
An FDA veteran, Woodcock has two stints heading up the Center for Drug Evaluation and Researchfrom 2008 until now and from 1994 to 2005. In between, she served in the FDA commissioners office. Most recently she served as part of Operation Warp Speed, overseeing COVID-19 therapy development.
She had initially been seen as a favorite to take the top job on a full-time basis but appeared to lose confidence from some key Washington insiders after the approval of Biogens expensive and controversial Alzheimers drug Aduhlem.
https://www.fiercebiotech.com/biotech/at-eleventh-hour-woodcock-shunned-by-biden-as-recycled-pick-califf-becomes-fda-commis
appalachiablue
(43,944 posts)- 'First human trial of Alzheimer's disease nasal vaccine to begin at Boston hospital, CBS News, Nov. 16, 21
Brigham and Women's Hospital will test the safety and efficacy of a nasal vaccine aimed at preventing and slowing Alzheimer's disease, the Boston hospital announced Tuesday. The start of the small, Phase I clinical trial comes after nearly 20 years of research led by Howard L. Weiner, MD, co-director of the Ann Romney Center for Neurologic Diseases at the hospital.
The trial will include 16 participants between the ages of 60 and 85, all with early symptomatic Alzheimer's but otherwise generally healthy. They will receive two doses of the vaccine one week apart, the hospital said in a press release. The participants will enroll from the Ann Romney Center.
A Phase I clinical trial is designed to establish the safety and dosage for a potential new medication. If it goes well, a much larger trial would be needed to test its effectiveness.
https://www.cbsnews.com/news/alzheimers-disease-nasal-vaccine-human-trial-to-begin-at-boston-hospital/
Donkees
(33,525 posts)appalachiablue
(43,944 posts)Ferrets are Cool
(22,613 posts)uponit7771
(93,505 posts)Skittles
(170,256 posts)ridiculous
